178 related articles for article (PubMed ID: 37349867)
1. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
Liu S; Huang C; Huang C; Huang Y; Yu Y; Wu G; Guo F; Jiang Y; Wan S; Zhu Z; Tian Y; Zhu J; Zhang J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2227779. PubMed ID: 37349867
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
[TBL] [Abstract][Full Text] [Related]
5. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
Chuang YC; Huang BY; Chang HW; Yang CN
Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
[TBL] [Abstract][Full Text] [Related]
7. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
9. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
11. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.
Chen W; Guo X; Zhang C; Ke D; Zhang G; Yu Y
Eur J Med Chem; 2019 Dec; 183():111734. PubMed ID: 31569004
[TBL] [Abstract][Full Text] [Related]
13. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
14. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
17. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
19. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
